Annals of Oncology 10:1181-1184, 1999
© 1999 European Society for Medical Oncology
research-article |
The role of positron emission tomography (PET) in the management of lymphoma patients
1Institute of Hematology and Medical Oncology ‘Seràgnoli’ University of Bologna Italy
2Department of Nuclear Medicine-PET Center, Caslelfranco Veneto Hospital Italy
3Institute of Diagnostic Radiology, University of Bologna Italy
Correspondence to: P. L. Zinzani, MD, Istituto di Ematologia e Oncologia Medica ‘Seràgnoli’, Policlinico S.Orsola, Via Massarenti 9, 40138 Bologna, Italy. E-mail: seragnol{at}kaiser.alma.unibo.it
Background: Treatment of both Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) with abdominal presentation at the time of diagnosis is often followed by detection of residual masses by computed tomography (CT). However, CT is usually unable to disciminate between residual tumor and fibrosis/necrosis. We investigated the ability of fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to differentiate between residual active tumor tissue and fibrosis.
Patients and methods: Forty-four patients with HD or aggressive NHL presenting abdominal involvement (41% with bulky mass) were studied with CT and PET at the end of chemotherapy ± radiation therapy.
Results: After treatment, seven patients had negative PET and CT, and none of them relapsed. The remaining 37 patients all had positive CT (abnormalities 
10%). All of the 13 who also had positive PET relapsed (100%). By contrast, there was only 1 (4%) relapse among the 24 patients who were positive at CT but negative at PET. The two-year actuarial relapse-free survival rate was 95% for those with negative PET compared with 0% for positive PET patients (P < 0.000000).
Conclusions: In lymphoma patients with abdominal masses who present CT positivity at restaging, PET should be considered the noninvasive imaging modality of choice for differentiating early recurrences or residual disease from fibrosis.
abdominal mass, aggressive NHL, CT scan, HD, PET
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. L. Zinzani, M. Tani, R. Trisolini, S. Fanti, V. Stefoni, M. Alifano, P. Castellucci, G. Musuraca, G. Dalpiaz, L. Alinari, et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma Haematologica, June 1, 2007; 92(6): 771 - 777. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Zinzani, M. Tani, S. Fanti, L. Alinari, G. Musuraca, E. Marchi, V. Stefoni, P. Castellucci, M. Fina, M. Farshad, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients Ann. Onc., August 1, 2006; 17(8): 1296 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Ansell and J. O. Armitage Management of Hodgkin Lymphoma Mayo Clin. Proc., March 1, 2006; 81(3): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Juweid Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 259 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Friedberg and V. Chengazi PET Scans in the Staging of Lymphoma: Current Status Oncologist, October 1, 2003; 8(5): 438 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Guay, M. Lepine, J. Verreault, and F. Benard Prognostic Value of PET Using 18F-FDG in Hodgkin's Disease for Posttreatment Evaluation J. Nucl. Med., August 1, 2003; 44(8): 1225 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study Radiology, May 1, 2003; 227(2): 353 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jerusalem, Y. Beguin, M. F. Fassotte, T. Belhocine, R. Hustinx, P. Rigo, and G. Fillet Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease Ann. Onc., January 1, 2003; 14(1): 123 - 130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Thomas, T. de Groot, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, and G. Verhoef Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma Ann. Onc., September 1, 2002; 13(9): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kostakoglu, M. Coleman, J. P. Leonard, I. Kuji, H. Zoe, and S. J. Goldsmith PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin's Disease J. Nucl. Med., August 1, 2002; 43(8): 1018 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Weihrauch, D. Re, K. Scheidhauer, S. Ansen, M. Dietlein, S. Bischoff, H. Bohlen, J. Wolf, H. Schicha, V. Diehl, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease Blood, November 15, 2001; 98(10): 2930 - 2934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S F Barrington Whole body applications of positron emission tomography in oncology Imaging, September 1, 2001; 13(3): 185 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schoder, J. Meta, C. Yap, M. Ariannejad, J. Rao, M. E. Phelps, P. E. Valk, J. Sayre, and J. Czernin Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma J. Nucl. Med., August 1, 2001; 42(8): 1139 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gossot, P. Girard, Eric de Kerviler, P. Brice, J.-D. Rain, T. Leblanc, and D. Grunenwald Thoracoscopy or CT-Guided Biopsy for Residual Intrathoracic Masses After Treatment of Lymphoma Chest, July 1, 2001; 120(1): 289 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Spaepen, S. Stroobants, P. Dupont, S. Van Steenweghen, J. Thomas, P. Vandenberghe, L. Vanuytsel, G. Bormans, J. Balzarini, C. De Wolf-Peeters, et al. Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods? J. Clin. Oncol., January 15, 2001; 19(2): 414 - 419. [Abstract] [Full Text] [PDF]
|
|